OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bello on Biomarkers in Follicular Lymphoma

August 31st 2018

Celeste Bello, MD, hematologist/oncologist, Moffitt Cancer Center, discusses investigational biomarkers in follicular lymphoma.

Dr. Ascierto on Triplet Therapy in BRAF+ Melanoma

August 31st 2018

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses investigational triplet therapies in patients with BRAF-positive melanoma.

Dr. Wirth on Takeaways From the SELECT Trial in Thyroid Cancer

August 31st 2018

Lori J. Wirth, MD, associate professor of medicine, Harvard Medical School, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, discusses takeaways from the SELECT trial in patients with thyroid cancer.

Dr. Krop on the Impact of Recent Advances in Breast Cancer

August 30th 2018

Ian E. Krop, MD, PhD, chief, Breast Oncology, Susan F. Smith Center for Women’s Cancers, clinical research director, Breast Oncology Center, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the impact of recent advances in breast cancer.

Dr. Brown on the Importance of Genetic Testing in Ovarian Cancer

August 30th 2018

Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of genetic testing in patients with ovarian cancer.

Dr. Riedel on the Treatment Landscape of Uterine Sarcomas

August 30th 2018

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the treatment landscape of uterine sarcomas.

Dr. Shiller on Hereditary Predisposition to Cancer

August 30th 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses a patient’s hereditary predisposition to cancer.

Dr. Ali on Whether Biosimilars Can Replace Biologics in Oncology

August 30th 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses whether biosimilars can replace biologics in oncology.

Dr. Kolberg Discusses Considerations With FDA-Approved Biosimilars

August 29th 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses considerations for FDA-approved biosimilars.

Dr. Reardon on a Personalized Neoantigen-Targeting Vaccine for GBM

August 29th 2018

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses a personalized neoantigen-targeting vaccine for patients with glioblastoma.

Dr. Jhaveri Discusses a Basket Trial of Taselisib in Solid Tumors

August 29th 2018

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a basket trial of taselisib in patients with PIK3CA-mutated locally advanced or metastatic solid tumors.

Dr. Yardley Shares Insight on the Impact of Biosimilars

August 29th 2018

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, shares insight on the potential impact of biosimilars in breast cancer.

Dr. Munshi on the Role of Checkpoint Inhibitors in Myeloma

August 29th 2018

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the role of checkpoint inhibitors in myeloma.

Dr. Wang on Genomic Analysis of Breast Cancer Risk in Pediatric Cancer Survivors

August 29th 2018

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses a genomic analysis of breast cancer risk in pediatric cancer survivors.

Dr. Ostertag on Emerging CAR T Product for Myeloma

August 29th 2018

Eric M. Ostertag, MD, PhD, chief executive officer, Poseida Therapeutics, Inc., discusses an emerging CAR T stem cell memory product for patients with relapsed/refractory multiple myeloma.

Dr. Hutchings on Subgroup Analysis of ECHELON-1 in Hodgkin Lymphoma

August 28th 2018

Martin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses a subgroup analysis of the ECHELON-1 study in Hodgkin lymphoma.

Dr. Yee Discusses the Categorization of Triple-Negative Breast Cancer

August 28th 2018

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplant, medical oncologist, University of Minnesota, discusses the categorization of patients with triple-negative breast cancer.

Dr. Kahl Discusses Unmet Needs in MCL

August 28th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses unmet needs in the treatment landscape of mantle cell lymphoma.

Dr. Forde on Updates to the TNM Staging System in Lung Cancer

August 28th 2018

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses updates to the tumor, node, metastasis (TNM) staging system in lung cancer.

Dr. Secord on the Management of Patients With Sarcoma

August 28th 2018

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the management of patients with sarcoma.